Abstract
Introduction
New agents are introduced each day to be used in the prevention and treatment of mucositis in cancer treatment. One of those agents is the Ankaferd hemostat. Ankaferd hemostat has pleiotropic effects and anti-infective characteristics in tissue healing.
Methods
The study was designed as a randomized controlled experimental study. The sample of the study comprised a total of 66 patients (33 patients in the Ankaferd hemostat group and 33 patients in the sodium bicarbonate group) with colorectal cancer who received FOLFOX combination chemotherapy treatment in the first cycle of chemotherapy to prevent mucositis. Participants who met the criteria were randomly assigned to the groups. Before the patient received chemotherapy, ECOG performance score and Oral Mucositis Grading Scale were applied on the 7th day and 15th day. The Ankaferd hemostat group brushed teeth at least twice a day for 2 min and gargled with Ankaferd hemostat twice for 2 min for 2 weeks. The sodium bicarbonate group brushed teeth at least 2 min a day and gargled with sodium bicarbonate 4 times for 2 min for 2 weeks. The Consolidated Standards of Reporting Trials diagram was used to illustrate the randomization of patients.
Results
When the Ankaferd hemostat group is compared with the sodium bicarbonate group, there is a significant difference in favor of the Ankaferd hemostat group in the mucositis grade on the 7th day and 15th day after chemotherapy (p < 0.05). In the binary logistic regression analysis, among the factors affecting the formation of mucositis on the 7th day, only neutrophil and thyroid-stimulating hormone (TSH) were included in the model, while only the TSH variable is statistically significant.
Conclusions
It was determined that Ankaferd hemostat is effective in preventing oral mucositis due to chemotherapy in adult patients diagnosed with colorectal cancer. In addition, it has been suggested to conduct new studies on the effectiveness of Ankaferd hemostat in the prevention of mucositis in different groups.
Trial registration
The study was registered at ClinicalTrials.gov (ID: NCT05438771, Date: 25.06.2022).
Similar content being viewed by others
Data availability
All data generated during this study are included in this published article.
References
Dekker E, Tanis PJ, Vleugels JLA et al (2019) Colorectal cancer. Lancet 394(10207):1467–1480. https://doi.org/10.1016/S0140-6736(19)32319-0
Sonis S (2007) Pathobiology of oral mucositis: novel insights and opportunities. J Support Oncol 5(9):3–11
Al-Ansari S, Zecha JAEM, Barasch A et al (2015) Oral mucositis induced by anticancer therapies. Curr Oral Heal Rep 2:202–221. https://doi.org/10.1007/s40496-015-0069-4
Gamelin BE, GueV DR et al (1999) Correlation between uracil and dihydrouracil plasma ratio, fluorouracil (5-FU) pharmacokinetic parameters, and tolerance in patients with advanced colorectal cancer: a potential ınterest for predicting 5-FU toxicity and determining optimal 5-FU dosage. J Clin Oncol 17(4):1105–1110
Ilhan Y, Sezgin Goksu S, Tatlı AM et al (2021) Does location of the tumor affect prognosis, survival, and relapse in patients with stage 3 colorectal cancers?. Akdeniz Med J 7(1):71–76. 10.17954
Elting LS, Cooksley C, Chambers M et al (2003) The burdens of cancer therapy: clinical and economic outcomes of chemotherapy-induced mucositis. Cancer 98(7):1531–1539
Nomura M, Kamata M, Kojima H, Hayashi K, Sawada S (2013) Irsogladine maleate reduces the incidence of fluorouracil-based chemotherapy-induced oral mucositis. Ann Oncol 24(4):1062–1066. https://doi.org/10.1093/annonc/mds584
Lalla RV, Gordon GB, Schubert M et al (2012) A randomized, double-blind, placebo-controlled trial of misoprostol for oral mucositis secondary to high-dose chemotherapy. Supportive Care in Cancer 20(8):1797–1804
Elad S, Karis Kin Fong CRVL, Yarom N et al (2020) MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy. Cancer 2020(1):4423–4431. https://doi.org/10.1002/cncr.33100
Atay MH, Aslan NA, Aktimur S, Buyukkaya P, Kelkitli E (2015) Safety and efficacy of Ankaferd hemostat ( ABS ) in the chemotherapy-induced oral mucositis. UHOD 25:166–171. https://doi.org/10.4999/uhod.15811
Goker H, Haznedaroglu I, Ercetın S et al (2008) Haemostatic actions of the folkloric medicinal plant extract Ankaferd Blood Stopper ®. J Int Med Res 36:163–170
Patıroglu T, Sahin E, Mustafa K et al (2018) Effectiveness of Ankaferd Blood Stopper in prophylaxis and treatment of oral mucositis in childhood cancers evaluated with plasma citrulline levels. Turk J Hematol 35(75–93):85–86. https://doi.org/10.4274/tjh.2017.0320
Sattari A, Shariati A, Shakiba MN et al (2019) Comparative study of the effect of licorice root extract mouthwash and combined mouthwash on the incidence and severity of chemotherapy-induced mucositis symptoms in colon cancer patients admitted to intensive care units. Jundishapur Journal of Chronic Disease Care 8(3). https://doi.org/10.5812/jjcdc.88641
Colin B, Cho M, Eastwood S et al (1996) Improving the quality of reporting of randomized controlled trials. JAMA 276(8):637–639. https://doi.org/10.1001/jama.1996.03540080059030
Worthington H, Clarkson J, Bryan G et al (2011) Interventions for preventing oral mucositis for patients with cancer receiving treatment. Cochrane Database Syst Rev (4). The Cochrane Collaboration. Published by John Wiley & Sons, Ltd. https://doi.org/10.1002/14651858.CD000978.pub5. Accessed 06 Jun 2023
Cheeseman SL, Joel SP, Chester JD et al (2002) A ‘modified de Gramont’ regimen of fluorouracil, alone and withoxaliplatin, for advanced colorectal cancer. Br J Cancer 87(4):393–394
Chaveli-López B, Bagán-Sebastián J (2016) Treatment of oral mucositis due to chemotherapy. J Clin Exp Dent 8(2):e201–e209. https://doi.org/10.4317/jced.52917
Celtek NY, Okan İ (2016) Patient evaluation and scales in palliative care. Klin Tıp Aile Hekim Derg 8(3):1–10
Valeh M, Kargar M, Mansouri A, Kamranzade H, Gholami K, Heidari K et al (2018) Factors affecting the incidence and severity of oral mucositis following hematopoietic stem cell. Int J Hematol Oncol Stem Cell Res 12(2):3–28
Saito H, Watanabe Y, Sato K et al (2014) Effects of professional oral health care on reducing the risk of chemotherapy-ınduced oral mucositis. Support Care Cancer 22:2935–2940. https://doi.org/10.1007/s00520-014-2282-4
Turkish Society of Endocrinology and Metabolism Society (TEMD) (2019) Obesity diagnosis and treatment guide 2019, 8th edn. Turkish Society of Endocrinology and Metabolism. Ankara, Bayt Publishing, pp 21–22
Djuric M, Hillier-Kolarov V, Belic A, Jankovic L (2006) Mucositis prevention by improved dental care in acute leukemia patients. Support Care Cancer 14(2):137–146. https://doi.org/10.1007/s00520-005-0867-7
Resendea AHM, Farias JM, Silva DDB et al (2019) Application of biosurfactants and chitosan in toothpaste formulation. Colloids Surf, B 181:77–84
Demir F, Ozsaker E, Ilce AO (2008) The quality and suitability of written educational materials for patients. J Clin Nurs 17(2):259–265
Charnock D, Shepperd S, Needham G, Gann R (1999) DISCERN: an instrument for judging the quality of written consumer health information on treatment choices. J Epidemiol Community Health 53(2):105–111
Gokdoğan F, Ozcan A, Kır E et al (2003) Are training booklets available? In: 2 International 9 National Nursing Congress Antalya, Turkey, Congress Book, pp 545–549
Ates A (2010) Educational software rating scale: validity and reliability study. IETC, p. 26–28. Available from: http://www.ajindex.com/dosyalar/makale/acarinde. date of access: 30.09.2021
Veneziano L, Hooper J (1997) A method for quantifying content validity of health related questionnaires. Am J Health Behav 21(1):67–70
Ameen IHB, Alzubaidee AF, Majid S (2020) Comparative evaluation of the efficacy of ice cubes versus sodium bicarbonate mouthwash both as prophylactic measure and as treatment of oral mucositis induced by systemic anticancer therapies. Tabari Biomed Stud Res J 1(4):13–17. https://doi.org/10.18502/tbsrj.v1i4.2244
Suresh AVS, Varma PP, Sinha S et al (2010) Risk-scoring system for predicting mucositis in patients of head and neck cancer receiving concurrent chemoradiotherapy [rssm-hn]. J Cancer Res Ther 6(4):448–451. https://doi.org/10.4103/0973-1482.77100
Niikura N, Nakatukasa K, Amemiya T et al (2020) Oral care evaluation to prevent oral mucositis in estrogen receptor-positive metastatic breast cancer patients treated with everolimus (Oral Care-BC): a randomized controlled phase III trial. Oncologist 25(2):220–230. https://doi.org/10.1634/theoncologist.2019-0382
Leukemia and Lymphoma Society (LLS) (2016) Dental and oral complications of cancer treatment facts. Leukemia and Lymphoma Society 29:1–3. https://www.lls.org/treatment/managing. Accessed 05 May 2022
Poulopoulos A, Papadopoulos P, Andreadis D (2017) Chemotherapy: oral side effects and dental interventions A review of the literature. Stomatological Dis Sci 1(2):35–49. https://doi.org/10.20517/2573-0002.2017.03
Ministry of Republic of Turkey, Turkey oral and dental health profile research report -2018. Available from: https://shgm.saglik.gov.tr/Eklenti/42552/0/tadsppdf.pdf?_date of access: 01.05.2023
Zheng Z, Zhao X, Zhao Q et al (2021) The effects of early nutritional ıntervention on oral mucositis and nutritional status of patients with head and neck cancer treated with radiotherapy. Front Oncol 10:1–11. https://doi.org/10.3389/fonc.2020.595632
Chandna S, Bathla M (2011) Oral manifestations of thyroid disorders and its management. Indian J Endocrinol Metab. 15(12):113–116. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3169868/pdf/IJEM-15-113. Accessed 02.05.2022
Loo WTY, Liu Q, Yip MCW et al (2013) Status of oral ulcerative mucositis and biomarkers to monitor posttraumatic stress disorder effects in breast cancer patients. Int J Biol Markers 28(2):168–173. https://doi.org/10.5301/jbm.5000025
Nome RV, Småstuen MC, Fosså SD, Kiserud CE, Åsvold BO, Bjøro T (2021) Thyroid hypofunction in aging testicular cancer survivors. Acta Oncol (Madr) 60(11):1452–1458. https://doi.org/10.1080/0284186X.2021.1958004
Rodrigues A, Aguiar M, Oliveira P et al (2020) Effect of cryotherapy in preventing mucositis associated with the use of 5-fluorouracil. Rev Latino-Am Enfermagem 28(e3363):1–10. https://doi.org/10.1590/1518-8345.3953.3363
Fatimah S, Sufiawati I, Wijaya I (2016) Characteristic patients with oral mucositis receiving 5-fu chemotherapy at Hasan Sadikin Hospital Bandung. Padjadjaran J Dent 28(3):205–209
Huang C, Huang M, Fang P et al (2019) Randomized double-blind, placebo-controlled trial evaluating oral glutamine on radiation-induced oral mucositis and dermatitis in headand neck cancer patients. Am J Clin Nutr 109:606–614
Oh S, Kwon H, Lee S et al (2007) A phase II study of oxaliplatin with low-dose leucovorin and bolus and continuous infusion 5-fluorouracil (Modified FOLFOX-4) for gastric cancer patients with malignant ascites. Jpn J Clin Oncol 37(12):930–935
Pattanayak L, Panda N, Dash MK, Mohanty S, Samantaray S (2016) Management of chemoradiation-induced mucositis in head and neck cancers with oral glutamine. J Glob Oncol 2(4):200–206. https://doi.org/10.1200/jgo.2015.000786
Velden V, Herbers A, Netea M, Blijlevens N (2014) Mucosal barrier injury, fever and infection in neutropenic patients with cancer: introducing the paradigm febrile mucositis. Br J Haematol 167(4):441–452. https://doi.org/10.1111/bjh.13113
Satheeshkumar PS, El-dallal M, Mohan MP (2021) Feature selection and predicting chemotherapy-induced ulcerative mucositis using machine learning methods. Int J Med Informatics 154:1–9
Anmar AT, Al-Shohani AD, Albasry Z, Altaee A (2019) Current topical trends and novel therapeutic approaches and delivery systems for oral mucositis management. J Pharm Bioall Sci 12:94–101. https://doi.org/10.4103/jpbs.JPBS
Kazemıan A, Kamıan S, Aghılı M et al (2008) Benzydamine for prophylaxis of radiation-ınduced oral mucositis in head and neck cancers: a double-blind placebo-controlled randomized clinical trial. Eur J Cancer Care 18:174–178
Adibi SS, Alcorn JL, Ono K, Lichtenberger LM (2018) Gender and smoking correlations of surfactant lipids and proteins in the saliva of dental patients. J Dent Maxillofac Surg 1(1):67–70. https://doi.org/10.18314/jdms.v1i1.1385
Lorini L, Perri F, Vecchio S et al (2022) Confounding factors in the assessment of oral mucositis in head and neck cancer. Support Care Cancer 30(10):8455–8463. https://doi.org/10.1007/s00520-022-07128-w
Feng L, Wang L (2013) Effects of alcohol on the morphological and structural changes in oral mucosa. Pakistan J Med Sci 29(4):1046–1049. https://doi.org/10.12669/pjms.294.3696
Pöschl G, Stickel F, Wang XD, Seitz HK (2004) Alcohol and cancer: genetic and nutritional aspects. Proceedings of the Nutrition Society 63(1):65–71. https://doi.org/10.1079/pns2003323
Schiött C, Höe H (1970) The origin and variation in number of leukocytes in thehuman saliva. J Periodont Res 5:36–41
Kumar N, Burke M, Brooke A et al (2018) The oral management of oncology patients requiring radiotherapy, chemotherapy and / or bone marrow transplantation. clinical guideline. Fac Den J:1–85. https://www.rcseng.ac.uk/-/media/files/rcs/fds/publication. Accessed 20 Apr 2022
Gebri E, Kiss A, Tóth F, Hortobágyi T (2020) Female sex as an independent prognostic factor in the development of oral mucositis during autologous peripheral stem cell transplantation. Sci Rep 10(1):1–12. https://doi.org/10.1038/s41598-020-72592-5
Mortezaee K, Ahmadi A, Haghi-Aminjan H et al (2019) Thyroid function following breast cancer chemotherapy: a systematic review. J Cell Biochem 120(8):12101–12107. https://doi.org/10.1002/jcb.28771
Schmidberger H, Rave-Fränk M, Kim S et al (2003) Radiation-induced mucositis and neutrophil granulocytes in oral mucosa. Strahlenther Onkol 179:667–672. https://doi.org/10.1007/s00066-003-1121-1
Cabrera-Jaimea S, Martínezc C, Ferro-García T et al (2018) Efficacy of plantago major, chlorhexidine 0.12% and sodium bicarbonate 5% solution in the treatment of oral mucositis in cancer patients with solid tumour: a feasibility randomised triple-blind phase III clinical trial. Europ J Oncol Nurs 32:40–47. https://doi.org/10.1016/j.ejon.2017.11.006
Acknowledgements
Paper extracted from doctoral thesis “The effects of Ankaferd Hemostat on preventing oral mucositis in colorectal cancer patients receiving chemotherapy,” presented to Bursa Uludag University Health Science Faculty, Bursa, Turkey. The research team would like to extend their gratitude to this university and all the participants who made this project possible.
Author information
Authors and Affiliations
Contributions
YK participated in the study design, data collection, data analysis, and implementation of the study; HY participated in the study design, analysis, and manuscript revision and supervised the research; YK provided an initial draft of the manuscript and participated in analysis, interpretation of data, and manuscript revision; HY, TE, and ICH participated in the study design and data analysis; ICH participated in the study design, analysis, and interpretation of data. All authors have read and approved the final manuscript.
Corresponding author
Ethics declarations
Ethics approval and consent to participate
This study was performed in line with the principles of the Declaration of Helsinki. Approval was granted by the Ethics Committee of Bursa Uludag University (Date.2020/ No.4/21–1). Informed consent was obtained from all individual participants included in the study.
Consent for publication
Patients signed informed consent regarding publishing their data and photographs.
Competing interests
The authors declare no competing interests.
Additional information
Publisher's note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
About this article
Cite this article
Karacan, Y., Yıldız, H., Evrensel, T. et al. The effects of Ankaferd hemostat on preventing oral mucositis in colorectal cancer patients receiving chemotherapy. Support Care Cancer 31, 385 (2023). https://doi.org/10.1007/s00520-023-07856-7
Received:
Accepted:
Published:
DOI: https://doi.org/10.1007/s00520-023-07856-7